[Global Pharmaceutical News, September 14, 2026]

1. Angelo de Claro, the newly appointed Director of the U.S. FDA’s Oncology Center of Excellence (OCE), gives his first interview, pledging continuity in regulatory innovation. Angelo de Claro, in his first interview since assuming leadership of the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE), outlined a regulatory agenda centered on strengthening organizational capacity and advancing regulatory modernization. This appointment brings stability to FDA oncology review operations amid the upcoming Senate confirmation hearing for FDA nominee Heidi Overton. 2. Oncology still accounts for nearly 40% of the global drug development pipeline; obesity has entered the top 10 therapeutic areas. Latest industry data show oncology continues to represent nearly two-fifths of the global drug development pipeline. Notably, obesity has risen into the top 10 therapeutic areas under active development. Chinese biotech companies are accelerating the overseas commercialization of weight-loss drugs through licensing partnerships. Additionally, approximately one-third of drugs currently in development target at least one rare disease. 3. Commercialization of mRNA-based personalized cancer vaccines faces multiple hurdles—including manufacturing challenges. Although Moderna and Merck’s mRNA cancer vaccine achieved success in Phase III trials—widely regarded by the industry as the dawn of a "personalized medicine revolution"—manufacturing bottlenecks remain one of the core challenges impeding commercialization. The industry must overcome numerous technical and operational barriers before scalable deployment can be realized. 4. Lonza bets on new spray-drying facility in Oregon, USA; CordenPharma invests €80 million to expand injectables capacity. Swiss CDMO giant Lonza plans to build a new spray-drying facility in Bend, Oregon, USA—demonstrating its firm commitment to high-value drugs and the U.S. market. Meanwhile, fellow Swiss CDMO CordenPharma is investing €80 million to expand injectables manufacturing capacity in Europe. 5. Samsung Biologics secures $262 million CDMO contract from European pharmaceutical company. Samsung Biologics has signed a $262 million CDMO contract with an unnamed European pharmaceutical company. While actively pursuing acquisitions to expand its peptide manufacturing capabilities, Samsung Biologics continues to win major orders for its core biologics contract development and manufacturing services.

Global and China Softgel Industry Survey and Development Outlook Forecast Report (2026–2032)

Table of Contents 1. Overview of the Softgel Market 1.1 Product Definition and Scope of Statistics 1.2 Major Softgel Types by Product Category 1.2.1 Growth Trends of Different Softgel Types in China: 2021 vs. 2025 vs. 2032 1.2.2 Gelatin-Based Softgels 1.2.3 Plant-Based/Non-Gelatin Softgels 1.2.4 Fish Gelatin Softgels 1.3 Major Softgel Types by Fill Material Characteristics 1.3.1 Growth Trends of Different Fill Material Types in China: 2021 vs. 2025 vs. 2032 1.3.2 Liquid-Filled Softgels 1.3.3 Suspension-Filled Softgels 1.3.4 Paste-Filled Softgels 1.4 Major Softgel Types by Release Profile 1.4.1 Growth Trends of Different Release Profiles in China: 2021 vs. 2025 vs. 2032 1.4.2 Immediate-Release Softgels 1.4.3 Enteric-Coated Softgels 1.4.4 Extended-Release Softgels 1.5 Major Applications of Softgels 1.5.1 Growth Trends of Different Applications in China: 2021 vs. 2025 vs. 2032 1.5.2 Dietary Supplements 1.5.3 Pharmaceuticals 1.5.4 Others (e.g., Cosmetics) 1.6 Current Status and Future Trends of China’s Softgel Industry (2021–2032) 1.6.1 China’s Softgel Market Revenue and Growth Rate (2021–2032) 1.6.2 China’s Softgel Sales Volume and Growth Rate (2021–2032) 2. Analysis of Key Softgel Manufacturers in the Chinese Market 2.1 Softgel Sales Volume and Market Share of Key Chinese Manufacturers 2.1.1 Softgel Sales Volume of Key Chinese Manufacturers (2021–2026) 2.1.2 Market Share of Softgel Sales Volume among Key Chinese Manufacturers (2021–2026) 2.2 Softgel Revenue and Market Share of Key Chinese Manufacturers 2.2.1 Softgel Revenue of Key Chinese Manufacturers (2021–2026) 2.2.2 Market Share of Softgel Revenue among Key Chinese Manufacturers (2021–2026) 2.2.3 Ranking of Key Chinese Manufacturers by Softgel Revenue in 2025 2.3 Softgel Pricing of Key Chinese Manufacturers (2021–2026) 2.4 Headquarters and Production Site Distribution of Key Chinese Softgel Manufacturers 2.5 Establishment Dates and Softgel Commercialization Timelines of Key Chinese Manufacturers 2.6 Softgel Product Types and Applications Offered by Key Chinese Manufacturers 2.7 Industry Concentration and Competitive Landscape Analysis 2.7.1 Industry Concentration Analysis: Top 5 Manufacturers’ Market Share in China (2025) 2.7.2 First-Tier, Second-Tier, and Third-Tier Softgel Manufacturers (Brands) in the Chinese Market and Their 2025 Market Shares 2.8 New Investments and M&A Activities

Lonza confirms 2026 outlook, upgrades midterm expectations

6 hours ago

Lonza AG reiterated its 2026 financial outlook, forecasting 11%-12% constant exchange rate sales growth and a 33%-34% core EBITDA margin despite expected foreign exchange headwinds.

chemweek

2026-10-17

Lonza confirms 2026 outlook, upgrades midterm expectations

Lonza confirms 2026 outlook, upgrades midterm expectations

FAQ